What are the odds nwbo will hit thier target price in the next year

The odds of NWBO hitting its target price in the next year depend on various factors, including market conditions, regulatory approvals, and the company's performance. Here's an analysis based on the available information:

1. Analyst Ratings and Target Price:
   • The average analyst target price for NWBO is $15.10 per share.
   • This represents a significant upside from the current price of $0.31 per share.
2. Regulatory Milestones and Timelines:
   • NWBO has submitted a Marketing Authorization Application (MAA) to the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for DCVax®-L for glioblastoma.
   • The EMA approval for DCVax®-L is estimated to occur between October 1, 2023, and June 1, 2024.
   • The FDA approval process typically takes several months after European approval.
3. Market Conditions and Investment Sentiment:
   • The stock has experienced a significant decline, with a 52-week low of $0.29 and a high of $1.09.
   • The company's recent announcements, such as the exclusive license from Roswell Park Comprehensive Cancer Center, could influence investor sentiment and potentially impact the stock price.
4. Company Performance and Clinical Trial Results:
   • NWBO's DCVax®-L has shown positive results in clinical trials, which could support regulatory approvals and potential market adoption.
   • The company's ongoing development efforts, such as the Flaskworks system, could also contribute to its future growth and market potential.
5. Risks and Uncertainties:
   • The target price is based on analysts' expectations and market conditions, which can change over time.
   • Realizing the target price depends on various factors, including regulatory approvals, clinical trial results, and market demand for the company's products.
   • The stock is considered high risk due to low liquidity and potential for significant price fluctuations.

In conclusion, while there is potential for NWBO to hit its target price in the next year, given the average analyst target price and the company's regulatory milestones, the outcome is not guaranteed. Investors should consider the risks and uncertainties associated with the stock's performance and the potential for fluctuations in the market.